C-terminal variants of the P2X7 receptor are associated with prostate cancer progression and bonemetastasis–evidence from clinical and pre-clinical data  

作　　者：Haiping Song Hector Manuel Arredondo Carrera Alexandria Sprules Ying Ji Tongsong Zhang Jiepei He Eleanor Lawrence Alison Gartland Jian Luo Ning Wang 

机构地区：[1]Department of Internal Medicine-Oncology,Qingdao Tumor Hospital,The Second Affiliated Hospital of Medical College of Qingdao University,Qingdao,Shandong 266042,P.R.China [2]The Mellanby Centre for Musculoskeletal Research,Department of Oncology and Metabolism,The University of Sheffield,Sheffield,South Yorkshire S102RX,UK [3]Yangzhi Rehabilitation Hospital(Sunshine Rehabilitation Centre),Tongji University School of Medicine,Shanghai 201619,P.R.China

出　　处：《Cancer Communications》2023年第3期400-404,共5页癌症通讯（英文）

摘　　要：Dear Editor Bone is the most common site for metastasis in prostate cancer(PCa),and identifying clinically useful biomarkers to predict the risk of currently incurable bone metastases is a major priority in PCa research.Extracellular adenosine triphosphate(ATP)was shown to be a major biochemical constituent of the tumor microenvironment and regulates the tumor and host interactions by acting at P2 purinergic receptors.Among the P2 receptors,the ion channel P2X purinergic receptor 7(P2X7R)has an unusually long C-terminus containing 200 amino acids,which forms the molecular basis for the unique bi-function of P2X7R promoting cancer cell proliferation or inducing membrane permeabilization and apoptosis,upon activation by a low or high concentration of ATP,respectively.

关 键 词：metastasis cancer CLINICAL 

分 类 号：R737.25[医药卫生—肿瘤]